Advertisement

Zirkulierende Tumormarker beim Prostatakarzinom

  • E. Bombardieri
  • E. Seregni

Zusammenfassung

Beim Prostatakarzinom gibt es eine Vielzahl zirkulierender Substanzen, die immunologisch oder biochemisch im Serum, im Prostatasekret, im Urin oder im Knochenmark nachgewiesen werden können [5]. Diese Verbindungen, üblicherweise „Tumormarker“genannt, erlauben es dem behandelnden Arzt, durch die einfache Untersuchung des Blutes oder anderer biologischer Flüssigkeiten Informationen über die Tumorerkrankung des Patienten zu erhalten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abul Fadl MAM, King EJ (1949) Properties of acid phosphatases of erythrocytes and of the human prostate gland. Biochem J 45: 51Google Scholar
  2. 2.
    Babson AL (1984) Alpha-naphthyl phosphate: the preferred substrate for acid phosphatase. Letter to the Editor. Clin Chem 30: 1418PubMedGoogle Scholar
  3. 3.
    Babson AL, Read PA (1959) A new assay for prostatic acid phosphatase in serum. Am J Clin Pathol 32: 88PubMedGoogle Scholar
  4. 4.
    Bais R, Huxtable A, Edwards JB (1983) Human prostatic acid phosphatase: properties of the native enzyme and the enzyme-antibody complex. Ann Clin Biochem 20: 374PubMedGoogle Scholar
  5. 5.
    Bombardieri E, Castellani MR, Marcelli G, Sciaraffa G, Buraggi GL (1982) Biological markers of prostatic cancer. In: Giuliani L, Santi L, Rosso R, Boccardo F, Bombardieri E (eds) International symposium on the management of prostatic carcinoma. Cederim, Milano, pp 39–48Google Scholar
  6. 6.
    Bombardieri E, Crippa F, Mattioli S et al. (1987) Circulating tumor markers for prostate cancer today: factors to be taken into consideration for their correct interpretation. In: New trends in diagnosis and treatment of prostatic cancer. Acta Medica, Edizioni e Congressi, pp 37–52Google Scholar
  7. 7.
    Bruce AW, Mahan DE, Morales A et al. (1979) An objective look at acid phosphatase determinations: comparison of biochemical and immunological methods. Br J Urol 51: 219Google Scholar
  8. 8.
    Bruce AW, Mahan DE, Belville WD (1980) The role of the radioimmunoassay for prostatic acid phosphatase in prostatic carcinoma. Urol Clin North Am 7: 645PubMedGoogle Scholar
  9. 9.
    Chen IW, Sperling MI, Maxon HR, Kaplan LA (1982) Stability of immunological activity of human acid phosphatase in serum. Clin Chem 28: 1163PubMedGoogle Scholar
  10. 10.
    Chu TM, Wang MC, Merrin C et al. (1978) Isoenzymes of human prostate acid phosphatase. Oncology 35: 198PubMedCrossRefGoogle Scholar
  11. 11.
    Collier D St J, Pain JA (1986) Acute and chronic retention of urine: relevance of raised serum prostatic acid phosphatase levels: a prospective study. Urology 27: 34PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper JF, Foti A, Herschman HH, Finkle W (1978) A solid phase radioimmunoassay for prostatic acid phosphatase. J Urol 119: 388PubMedGoogle Scholar
  13. 13.
    Dass S, Bowen NL, Bagshawe KD (1980) Rapid, fully automated radioimmunoassay of prostatic acid phosphatase in serum. Clin Chem 26: 1583PubMedGoogle Scholar
  14. 14.
    Davies SN, Gochman N (1983) Evaluation of a monoclonal antibody-based immunoradio metrie assay for prostatic acid phosphatase. Am J Clin Pathol 79: 114PubMedGoogle Scholar
  15. 15.
    Debruyne FM, Munster PJ van, Groeningen JC van (1984) Radioimmunoassay ( RIA) for prostatic acid phosphatase in patients with prostatic carcinoma. Urol Res 12: 233PubMedCrossRefGoogle Scholar
  16. 16.
    El Shirbiny A, Bhargava A, Beckley S et al. (1984) Comparison of immunologic and enzymatic assay of prostatic acid phosphatase for follow-up and assessment of clinical status of stage D prostate cancer. J Surg Oncol 26: 526Google Scholar
  17. 17.
    Ewen LM, Spitzer RW (1976) Improved determination of prostatic acid phosphatase (sodium thymolphthalein monophosphate substrate). Clin Chem 22: 627PubMedGoogle Scholar
  18. 18.
    Fishman WH, Lerner FA (1953) A method for estimating serum acid phosphatase of prostatic origin. J Biol Chem 200: 89PubMedGoogle Scholar
  19. 19.
    Fornara P, Sturm W, Fabricius PG, Schmiedt E (1987) Klinisehe Relevanz der radioimmuno logischen Bestimmung des prostataspezifischen Antigens ( PSA) beim Prostatakarzinom. Urologe [A] 26: 158PubMedGoogle Scholar
  20. 20.
    Foti AG, Herschman HH, Cooper JF (1977) Comparison of human prostatic phosphatase by measurement of enzymatic activity and by radioimmunoassay. Clin Chem 23: 95PubMedGoogle Scholar
  21. 21.
    Franchimont P, Bouffioux C, Reuter A et al. (1983) Radioimmunoassay of prostatic acid phosphatase: validation and clinical application. Int J Cancer 31: 149PubMedCrossRefGoogle Scholar
  22. 22.
    Graves HCB, Sensabaugh GF, Blake ET (1985) Postcoital detection of a male-specific semen protein: application to the investigation of rape. N Engl J Med 312: 338PubMedCrossRefGoogle Scholar
  23. 23.
    Greene FR, Thompson IM (1974) The effects of various manipulations on serum phosphatase level in benign disease. J Urol 112: 232PubMedGoogle Scholar
  24. 24.
    Griffith JC (1980) Prostate-specific acid phosphatase: re-evaluation of radioimmunoassay in diagnosing prostatic disease. Clin Chem 26: 433Google Scholar
  25. 25.
    Killian CS, Vargas FP, Lee CL et al. (1980) Quantitative counterimmunoelectrophoresis assay for prostatic acid phosphatase. Invest Urol 18: 219PubMedGoogle Scholar
  26. 26.
    Killian CS, Yang N, Emrich LJ et al. (1985) Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 45: 886PubMedGoogle Scholar
  27. 27.
    Killian CS, Emrich LJ, Vargas FP et al. (1986) Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 76: 179PubMedGoogle Scholar
  28. 28.
    Klein LA, Shapiro P (1981) Role of acid phosphatase measurement in management of prostate cancer. Urology 17: 550PubMedCrossRefGoogle Scholar
  29. 29.
    Kontturi M, Vihko P, Lukkarinen O et al. (1985) Immunoreactive prostate-specific acid phosphatase in prostatic cancer. Scand J Clin Lab Invest 45 /179: 67Google Scholar
  30. 30.
    Kuriyama M, Wang MC, Papsidero LD et al. (1980) Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40: 4658PubMedGoogle Scholar
  31. 31.
    Kuriyama M, Wang MC, Lee CL et al. (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41: 3874PubMedGoogle Scholar
  32. 31a.
    Kuriyama M (1986) Report for Fundamental Scientific Research 5780303 from Ministry of Education, JapanGoogle Scholar
  33. 32.
    Liedtke RJ, Batjer JD (1984) Measurement of prostatic-specific antigen by radioimmunoassay. Clin Chem 30: 649PubMedGoogle Scholar
  34. 33.
    Lilja HA (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899PubMedCrossRefGoogle Scholar
  35. 34.
    Lillehoj HS, Choe BK, Rose NR (1982) Monoclonal antibodies to human prostatic acid phosphatase: Probes for antigenic study. Proc Natl Acad Sci USA 79: 5061–5065PubMedCrossRefGoogle Scholar
  36. 35.
    Lindholm GR, Stirton S, Liedtke RJ et al. (1980) Prostatic acid phosphatase by radioimmunoassay: sensitivity compared with enzymatic assay. JAMA 244: 2071PubMedCrossRefGoogle Scholar
  37. 36.
    Maatman TJ, Gupta MK, Montie JE (1984) The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate. J Urol 132: 58PubMedGoogle Scholar
  38. 37.
    McCarthy RC, Jakubowski HV, Markowitz H (1983) Human prostatic acid phosphatase: purification, characterization, and optimization of conditions for radioimmunoassay. Clin Chim Acta 132: 287PubMedCrossRefGoogle Scholar
  39. 38.
    Mensink HJ, Marrink J, Hindriks FR (1983) Prostatic acid phosphatase: comparison of ra dioimmunoassay and enzyme activity assay. J Urol 129: 1136PubMedGoogle Scholar
  40. 39.
    Morishita N, Minami Y, Ogawa S et al. (1984) Purification and enzyme immunoassay of tumor markers for prostate cancer: Prostatic acid phosphatase, prostate-specific antigen and creatine kinase BB. Jpn J Urol 75: 404Google Scholar
  41. 40.
    Nilsson T, Miintzing J (1973) Histochemical and biochemical enzyme studies in prostatic carcinomatous tissue before and during treatment with estrogen. Scand J Urol Nephrol 7: 14PubMedCrossRefGoogle Scholar
  42. 41.
    Paganuzzi M, Ferrara GB (1986) La fosfatasi acida prostatica: marcatore tumorale classico del carcinoma prostatieo. In: Boccardo F, Bombardieri E, Fabris F (eds) I biomarcatori del carcinoma della prostata. Schiitztor, Konstanz, p 65Google Scholar
  43. 42.
    Paulson DF, Berry WR, Cox EB et al. (1979) Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J Natl Cancer Inst 63: 615PubMedGoogle Scholar
  44. 43.
    Pontes JE, Chu TM, Slack N et al. (1982) Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. J Urol 128: 1216PubMedGoogle Scholar
  45. 44.
    Robey EL, Schellhammer PF, Wright GL et al. (1985) Cancer serum index and prostatic acid phosphatase for detection of progressive prostatic cancer. J Urol 134: 787PubMedGoogle Scholar
  46. 45.
    Romas NA, Shaw LM, Hsu KC et al. (1982) Clinical comparison of immunological assay for determining prostatic acid phosphatase. Ann NY Acad Sci 390: 104PubMedCrossRefGoogle Scholar
  47. 46.
    Roy AV, Brower ME, Hayden JE (1971) Sodium thymolphthalein monophosphatase: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17: 1093PubMedGoogle Scholar
  48. 47.
    Shaw LM, Yang N, Brooks JJ et al. (1981) Immunochemical evaluation of the organ specificity of prostatic acid phosphatase. Clin Chem 27: 1505PubMedGoogle Scholar
  49. 48.
    Siddall JK, Cooper EH, Newling DWW, Robinson MRG, Whelan P (1986) An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol 12: 123PubMedGoogle Scholar
  50. 49.
    Siddall JK, Shetty SD, Cooper EH (1986) Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. Clin Chem 32: 2040PubMedGoogle Scholar
  51. 50.
    Stamey TA, Yang N, Hay AR et al. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909PubMedCrossRefGoogle Scholar
  52. 51.
    Van Cangh PJ, Opsomer R, De Nayer P (1982) Serum prostatic acid phosphatase determination in prostatic disease: a critical comparison of an enzymatic and a radioimmunologic assay. J Urol 128: 1212PubMedGoogle Scholar
  53. 52.
    Wajsman Z, Chu TM, Saroff J et al. (1979) Two new, direct and specific methods of acid phosphatase determination. National field trial. Urology 13: 8PubMedCrossRefGoogle Scholar
  54. 53.
    Watson RA, Tang DB (1980) The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303: 497PubMedCrossRefGoogle Scholar
  55. 54.
    Watt KWK, Lee PJ, M’Timkulu T et al. (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • E. Bombardieri
  • E. Seregni
    • 1
  1. 1.Istituto Nazionale per lo Studio e la Cura dei TumoriMilanoItaly

Personalised recommendations